Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Abeona Therapeutics (ABEO) over the last 14 years, with Q3 2025 value amounting to $2.5 million.

  • Abeona Therapeutics' Capital Expenditures rose 52376.24% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 29573.79%. This contributed to the annual value of $2.4 million for FY2024, which is 63897.28% up from last year.
  • Per Abeona Therapeutics' latest filing, its Capital Expenditures stood at $2.5 million for Q3 2025, which was up 52376.24% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Capital Expenditures ranged from a high of $3.2 million in Q4 2021 and a low of $2000.0 during Q3 2022
  • Over the past 5 years, Abeona Therapeutics' median Capital Expenditures value was $403000.0 (recorded in 2021), while the average stood at $771111.1.
  • As far as peak fluctuations go, Abeona Therapeutics' Capital Expenditures skyrocketed by 974242.42% in 2021, and later crashed by 9950.25% in 2022.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Capital Expenditures stood at $3.2 million in 2021, then plummeted by 99.23% to $25000.0 in 2022, then surged by 48.0% to $37000.0 in 2023, then skyrocketed by 1537.84% to $606000.0 in 2024, then surged by 315.84% to $2.5 million in 2025.
  • Its Capital Expenditures stands at $2.5 million for Q3 2025, versus $2.9 million for Q2 2025 and $1.4 million for Q1 2025.